Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ATXNYSE:FTTCVE:HEMCVE:NSCICVE:PAS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATXCosta$2,934.88$0.00▼$0.00N/AN/AN/AN/AFTTFederated Enhanced Treasury Income Fund$0.00$12.81▼$13.82N/AN/A24,050 shsN/AHEMHemostemixC$0.13-3.7%C$0.11C$0.04▼C$0.43C$18.95M0.2419,641 shs3,803 shsNSCINanalysis ScientificC$0.25C$0.27C$0.25▼C$0.46C$28.27M0.7265,490 shs115,500 shsPASPascal BiosciencesC$0.02-25.0%C$0.02C$0.02▼C$0.10C$984K1.5152,289 shs4,000 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATXCosta0.00%0.00%0.00%0.00%0.00%HEMHemostemix-3.70%-3.70%+13.04%+44.44%+85.71%NSCINanalysis Scientific0.00%0.00%+2.04%-10.71%-40.48%PASPascal Biosciences0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationATXCostaN/AN/AN/AN/AN/AN/AN/AN/AFTTFederated Enhanced Treasury Income FundN/AN/AN/AN/AN/AN/AN/AN/AHEMHemostemixN/AN/AN/AN/AN/AN/AN/AN/ANSCINanalysis ScientificN/AN/AN/AN/AN/AN/AN/AN/APASPascal BiosciencesN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATXCosta 0.00N/AN/AN/AFTTFederated Enhanced Treasury Income Fund 0.00N/AN/AN/AHEMHemostemix 0.00N/AN/AN/ANSCINanalysis Scientific 0.00N/AN/AN/APASPascal Biosciences 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATXCostaN/AN/AN/AN/AN/AN/AFTTFederated Enhanced Treasury Income FundN/AN/AN/AN/AN/AN/AHEMHemostemixN/AN/AC$0.01 per share10.77C($0.10) per shareN/ANSCINanalysis ScientificC$39.47M0.72C$0.03 per share8.93C$0.21 per share1.19PASPascal BiosciencesN/AN/AC$0.00 per share55.00C($0.02) per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATXCostaN/AN/A0.00N/AN/AN/AN/AN/AN/AFTTFederated Enhanced Treasury Income FundN/AN/A0.00N/AN/AN/AN/AN/AN/AHEMHemostemix-C$5.00M-C$0.03N/A∞N/AN/A37.07%-349.24%N/ANSCINanalysis Scientific-C$12.93M-C$0.12N/A∞N/A-32.75%-38.02%-7.55%N/APASPascal BiosciencesN/A-C$0.01N/A∞N/AN/AN/A-340.40%N/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthATXCostaN/AN/AN/AN/AN/AFTTFederated Enhanced Treasury Income FundN/AN/AN/AN/AN/AHEMHemostemixN/AN/AN/AN/AN/ANSCINanalysis ScientificN/AN/AN/AN/AN/APASPascal BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATXCostaN/AN/AN/AFTTFederated Enhanced Treasury Income FundN/AN/AN/AHEMHemostemix-55.070.040.48NSCINanalysis Scientific71.721.421.11PASPascal Biosciences882.790.030.17Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATXCostaN/AFTTFederated Enhanced Treasury Income FundN/AHEMHemostemixN/ANSCINanalysis Scientific0.03%PASPascal BiosciencesN/AInsider OwnershipCompanyInsider OwnershipATXCostaN/AFTTFederated Enhanced Treasury Income FundN/AHEMHemostemix10.43%NSCINanalysis Scientific3.95%PASPascal Biosciences15.43%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableATXCostaN/AN/AN/ANot OptionableFTTFederated Enhanced Treasury Income FundN/AN/AN/ANot OptionableHEMHemostemixN/A145.73 millionN/ANot OptionableNSCINanalysis Scientific249113.06 millionN/ANot OptionablePASPascal Biosciences665.59 millionN/ANot OptionableHEM, NSCI, ATX, FTT, and PAS HeadlinesRecent News About These CompaniesLooking back on the fights that defined Jean Pascal's careerJuly 1 at 2:59 AM | dazn.comDJ.K. Rowling Takes Brutal Swipe At Pedro Pascal Following His Recent CommentsJuly 1 at 2:59 AM | msn.comPedro Pascal Says Marvel Asked Him to Pull Back From Doing One Specific Thing While Filming ‘The Fantastic Four: First Steps’July 1 at 2:59 AM | msn.comLux Pascal’s Deluxe DebutJuly 1 at 2:59 AM | hollywoodreporter.comHJean Pascal and Michal Cieslak make weight for Saturday boutJune 29 at 10:31 AM | boxingscene.comBWR Zach Pascal Will Likely Need to Make His Mark on Special Teams for NY GiantsJune 29 at 10:31 AM | msn.comPedro Pascal, internet heartthrob, real-life iconJune 29 at 10:31 AM | msn.comJean Pascal falls in hometown letdown against Michal CieslakJune 29 at 10:31 AM | boxingscene.comBPedro Pascal Says J.K. Rowling Makes Him ‘F—ing Sick’ For Role In Court Ruling That Says Trans Women Aren’t Legally WomenJune 29 at 10:31 AM | uinterview.comUPedro Pascal's Forgotten Crime Show With 89% On RT Is Still A Must-Watch A Decade LaterJune 29 at 10:31 AM | msn.comPedro Pascal Landed Two DC Roles Before He Ended Up With MarvelJune 28 at 2:36 PM | comicbook.comCPedro Pascal Landed Two DC Roles Before He Ended Up With MarvelJune 28 at 2:36 PM | comicbook.comCPedro Pascal Faces Criticism: Mister Fantastic Role Sparks DebateJune 26, 2025 | devdiscourse.comDWhat did Pedro Pascal say? Actor doubles down on JK Rowling criticism over trans rights opinionJune 26, 2025 | soapcentral.comSRobert Downey Jr. is the biggest Pedro Pascal fanJune 25, 2025 | msn.comPedro Pascal Ranks Himself Last in the ‘Fantastic Four’ Cast on Humor, Talent and Intelligence | VideoJune 25, 2025 | msn.comPedro Pascal Won’t Stand for Anti-Trans Comments From J.K. Rowling or Any Other ‘Bullies’June 25, 2025 | rollingstone.comRPedro Pascal explains calling out J.K. Rowling in social media commentJune 25, 2025 | thenews.com.pkTPedro Pascal says he decided to call JK Rowling a ‘heinous loser’ because ‘bullies make me sick’June 25, 2025 | msn.comPedro Pascal Speaks Out on His Past Comments About J.K. Rowling: ‘Bullies Make Me F**king Sick’June 24, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Penny Stocks Analysts Believe Are Headed HigherBy Chris Markoch | June 4, 2025View 3 Penny Stocks Analysts Believe Are Headed HigherThese 3 Dividend Stocks Combine Strong Yields With UpsideBy Chris Markoch | June 20, 2025View These 3 Dividend Stocks Combine Strong Yields With UpsideValue vs Growth Ratio Hits Cycle Low—Top Value Picks to BuyBy Gabriel Osorio-Mazilli | June 30, 2025View Value vs Growth Ratio Hits Cycle Low—Top Value Picks to Buy3 Tightly-Held Growth Stocks Set Up for Short SqueezesBy Thomas Hughes | June 9, 2025View 3 Tightly-Held Growth Stocks Set Up for Short Squeezes3 Safe Buy-and-Hold Dividend Stocks With Strong Balance SheetsBy Chris Markoch | July 1, 2025View 3 Safe Buy-and-Hold Dividend Stocks With Strong Balance SheetsHEM, NSCI, ATX, FTT, and PAS Company DescriptionsCosta NASDAQ:ATXCosta Inc, formerly A. T. Cross Company is a designer and marketer of branded personal accessories, including writing instruments, reading glasses, personal and business accessories and sunglasses. The Company's Cross Optical Group (COG) consists of its wholly owned subsidiary, Cross Optical Group, Inc. and is the legal entity of the Company's two sunglass brands: Costa and Native. The Company's COG designs, manufactures and markets polarized sunglasses under the brand names Costa and Native. The Company's brands offer sunglasses in more than 75 styles and 25 lens options. In September 2013, the Company sold its Cross Accessory Division and the rights to the A.T. Cross name, which was associated with the writing instrument business. Effective February 3, 2014, Essilor International SA acquired Costa Inc.Federated Enhanced Treasury Income Fund NYSE:FTTFederated Premier Intermediate Municipal Income Fund (the Fund) is a diversified, closed-end management investment company. The Fund's investment objective is to provide current income exempt from federal income tax, including the federal alternative minimum tax (AMT). The Fund's portfolio of investments include various sectors namely transportation, special tax, hospital, education, public power, senior care, water and sewer, general obligation-local, industrial development bond/pollution control revenue and general obligation-state. The Fund invests in intermediate-term, tax-exempt municipal bonds diversified among states, sectors and issuers. Federated Investment Management Company is the advisor of the Fund.Hemostemix CVE:HEMC$0.13 -0.01 (-3.70%) As of 06/30/2025 02:58 PM EasternHemostemix Inc., a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia. The company also develops NCP-01, which is preclinical trial to evaluate effect on neuropathic pain and motor function recovery. Hemostemix Inc. is headquartered in Calgary, Canada.Nanalysis Scientific CVE:NSCIC$0.25 0.00 (0.00%) As of 06/30/2025 03:59 PM EasternNanalysis Scientific Corp. engages in the development, manufacture, and sale of magnetic resonance products in the United States, Canada, Europe, Asia, and internationally. The company operates through four segments: Nanalysis, RS2D, K'Prime, and Corporate. It offers nuclear magnetic resonance (NMR) spectrometers; software module packages; cutting-edge electronics components for precision analytical instruments; and services for its NMR technologies. It serves pharmaceutical, security, biotech, nutraceutical, chemical, food, materials, medical, and education industries. The company is headquartered in Calgary, Canada.Pascal Biosciences CVE:PASC$0.02 -0.01 (-25.00%) As of 12/5/2022Pascal Biosciences Inc., a biotechnology company, engages in the research and development of products for the treatment of cancer, and for the improvement of the immune system. The company's development portfolio includes PAS-403, a mitosis inhibitor that blocks cell division for the treatment of glioblastoma and brain metastases originating from other cancers; and PAS-393, an immune-stimulatory cannabinoid designed to restore the immunogenicity of tumor cells with checkpoint inhibitor therapy for use in cancer treatment. It is also developing a B-cell targeted antibody for acute lymphoblastic leukemia and B cell lymphomas; and cannabinoid therapeutic products for the treatment of COVID-19. The company has an exclusive license agreement with the University of Washington to develop a cannabinoid-based product for the treatment of glioblastoma multiforme and brain metastases; and a collaborative research agreement with SoRSE Technology Corporation to advance PAS-393 into clinical testing. Pascal Biosciences Inc. was incorporated in 2011 and is headquartered in Seattle, Washington. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 2 Reasons to Buy Trade Desk Stock Now and 1 Warning Sign Toast Stock: A Fast-Growing Mid-Cap Eyeing Further Upside Breakout Alert: Disney Stock Hits Multi-Year High 2 Under the Radar Space & Defense Stocks With Huge Potential Palantir’s $100M Nuclear OS Pact Boosts Bullish Case Forget IBM: Accenture’s AI Momentum Is Your Next Buy Joby Stock Soars as Piloted Flights in Dubai Signal a New Era Tesla’s Robotaxi Hype Fuels Bullish Price Targets to $500 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
